An interventional study of BraveBot and Self-Guided Exposure Therapy Homework in Anxiety Disorders and OCD, sponsored by Massachusetts General Hospital. Not yet recruiting at 3 sites in United States. Open to participants aged 12 Years to 22 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Anxiety Disorders by Massachusetts General Hospital — 14 open to participants now, 20 under way, none of them phase 3. Anxiety Disorders · Massachusetts General Hospital.
Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, this one is the 40th largest by planned enrollment of the 64 interventional ones that give a count, is one of 2 that started in 2027, is one of 40 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 65th registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →14 of the 67 studies in Anxiety Disorders by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 12–17
Massachusetts General Hospital · Sites in United States
Ages 7–17
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 12 Years to 22 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 4 · Phase 4 11
First in 1998; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 63 across the 64 interventional studies, 123 across the 2 observational. Of the 44 that completed or were terminated, 27 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
8 of the studies in Anxiety Disorders by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639827Massachusetts General HospitalA Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion | 2027-01 |
| NCT06226155Massachusetts General HospitalAdaptation of an Intervention Addressing Barriers to PrEP Use Among Pregnant Women in Zimbabwe | 2027-01-01 |
| NCT06316804Massachusetts General HospitalMobile Mental Health Stigma Reduction Intervention Among Black Adults | 2027-01-01 |
| NCT06654414Massachusetts General HospitalAdapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke | 2027-03-31 |
| NCT06557005Massachusetts General HospitalFacilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions | 2027-05-23 |
Add all 8 to your calendar (.ics) → With an account.
Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing a digital tool called BraveBot for young people who are receiving cognitive behavioral therapy (CBT) for anxiety, OCD, or related problems. BraveBot is a computer program, not a person. It talks with youth through their phone or computer while they do "face-your-fears"-style exposure therapy homework that their therapist has assigned. Sometimes an exposure is done with BraveBot's real-time coaching, and sometimes on their own; after each exposure, youth answer a few short questions about how it went.
Rather than dividing participants into separate groups, the study randomizes each individual exposure homework assignment. Every time a young person opens an eligible exposure, the system makes a 1:1 random assignment deciding whether that exposure is completed with BraveBot's support or independently (self-guided).
The main goal is to learn whether using BraveBot helps youth understand their exposure assignments better, put in more effort, stick with exposures when they are hard, feel more capable, and find exposures more helpful in "fighting back" against anxiety. The study also examines whether BraveBot increases the likelihood that assigned exposures are completed, and explores effects on anxiety symptoms and how safe, easy to use, and useful BraveBot feels for youth, their therapists, and parents.
BraveBot does not replace the therapist, diagnose, or design exposures; it only supports the homework the clinician has assigned, and is used under clinician oversight. A built-in safety system can detect possible risk-related language, pause the session, show crisis resources (such as 988), and notify the treating clinician. The study is conducted within routine outpatient psychology clinics at Mass General Brigham. Up to 40 youth ages 12-22 will take part.
Design. Open-label, within-participant, exposure-instance-level randomized trial embedded in routine outpatient exposure-based CBT at Mass General Brigham clinics. The unit of randomization is the individual clinician-assigned, "BraveBot-eligible" exposure homework instance. Each time a youth opens the link for a BraveBot-eligible exposure delivered via SMS reminder, the backend system immediately randomizes that single instance 1:1 to BraveBot-assisted vs self-guided completion.
Intervention. BraveBot is a scope-limited, clinician-supervised, large language model (GPT)-powered audio-to-audio conversational assistant (provided by TheraLoop AI, Inc.) that supports completion of clinician-assigned exposure homework. For BraveBot-assisted instances it clarifies the assignment and rationale, collects Subjective Units of Distress (SUDS) ratings and expectations, encourages persistence when anxiety rises, prompts about safety behaviors and "white-knuckling" at mid-exposure check-ins, and guides brief end-of-exposure reflection. It does not diagnose, generate exposure hierarchies, or make treatment decisions. For self-guided instances, the youth completes the same assigned exposure independently and then completes the same post-exposure survey.
Aims.
Aim 1 (primary): whether BraveBot improves exposure-homework QUALITY, assessed by five youth-reported 0-100 ratings per completed instance (Effort, Perceived Capability, Understanding, Ability to Continue, Perceived Helpfulness).
Aim 2 (secondary): whether BraveBot increases exposure-homework ADHERENCE (probability that a randomized instance is completed).
Aims 3-5 (exploratory): preliminary effects on clinical outcomes (RCADS anxiety, CALIS-C life interference, IUSC intolerance of uncertainty) and associations with exposure-related processes; acceptability/usability/burden among youth, clinicians, and parents; and the performance and burden of BraveBot's automated risk-detection and clinician-notification (safety) workflow.
Participants and schedule. Up to 40 youth ages 12-22 with a clinical or subclinical anxiety or related disorder for which exposure-based CBT is indicated. BraveBot access remains active for up to 45 homework-reminder days (about six weeks), with a 12-week backstop (i.e., 84 calendar days). Standardized self-report measures are collected at baseline (pre-BraveBot), at the end of the active BraveBot period, and at a \~3-week follow-up. A separate population of up to 10 clinicians may voluntarily enroll to use the BraveBot system with their patients and complete surveys about their experience.
Analysis. Primary outcomes are analyzed with linear mixed-effects models (fixed effect of condition; random intercepts for youth, and clinician/site as needed), with Benjamini-Hochberg false-discovery-rate correction across the five co-primary outcomes. Adherence is analyzed with a binomial-logit generalized linear mixed-effects model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA (present at enrollment):
The investigators will also recruit up to 10 clinicians at participating programs who may use the BraveBot system with their patients (who have enrolled in the study independently) and complete brief baseline and end-of-study surveys.
Exposure instances randomized to this condition are completed with BraveBot, an LLM-powered audio-to-audio conversational assistant that provides real-time, structured coaching: clarifying the assigned exposure and its rationale, collecting SUDS ratings, encouraging persistence, prompting about safety behaviors and 'white-knuckling' at mid-exposure check-ins, and guiding brief post-exposure reflection.
Behavioral: BraveBot
Exposure instances randomized to this condition are completed independently by the youth (standard self-guided homework), without BraveBot coaching; the youth then completes the same brief post-exposure survey.
Behavioral: Self-Guided Exposure Therapy Homework
Scope-limited, clinician-supervised, GPT-powered audio-to-audio conversational assistant delivered via a secure web link in SMS reminders. Supports clinician-assigned exposure homework by clarifying instructions and rationale, collecting SUDS, encouraging persistence, prompting about safety behaviors and white-knuckling, and guiding post-exposure reflection. Includes an automated risk-detection workflow that pauses the session, shows crisis resources, and notifies the treating clinician.
Also known as: BraveBot by TheraLoop AI, Inc.
The youth completes the same clinician-assigned exposure independently, without BraveBot coaching (standard between-session homework).
Exposure Quality -- Effort (0-100)
Youth-reported effort put into the exposure, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater effort (better).
Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Exposure Quality -- Perceived Capability (0-100)
Youth-reported sense of being capable to approach or handle anxiety-provoking situations, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater perceived capability (better).
Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Exposure Quality -- Understanding (0-100)
Youth-reported understanding of what to do and why during the exposure, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater understanding (better).
Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Exposure Quality -- Ability to Continue When Distressed (0-100)
Youth-reported ability to stay with the exposure when it was difficult or distressing, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater ability to continue (better).
Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Exposure Quality -- Perceived Helpfulness (0-100)
Youth-reported helpfulness of the exposure in reducing anxiety, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater perceived helpfulness (better).
Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Exposure-homework Adherence
Proportion of randomized exposure instances classified as Complete (vs. Incomplete), compared between BraveBot-assisted and self-guided conditions. Completion is determined automatically from condition-specific workflow flags. Reported as a proportion (0-1); a higher completion proportion for BraveBot-assisted vs. self-guided is better.
Time frame: For each randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).
Revised Children's Anxiety and Depression Scale (RCADS) - Total Anxiety (youth-report)
Anxiety symptom measure; each item scored 0 (Never) to 3 (Always). The Total Anxiety score is the sum of the five anxiety subscales (separation anxiety, social phobia, generalized anxiety, panic, obsessive-compulsive). Total Anxiety score range 0-111; higher scores indicate greater anxiety symptoms (worse).
Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).
Child Anxiety Life Interference Scale (CALIS) (youth-report)
Self-report measure of anxiety-related interference in the child's daily life. Each of the 8 items are rated on a 0-4 scale. Total score range 0-32; higher scores indicate greater anxiety-related life interference (worse).
Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).
Intolerance of Uncertainty Scale-Child (IUSC) (youth-report)
Self-report measure of intolerance of uncertainty; items rated 1-5. Total score range 27-135; higher scores indicate greater intolerance of uncertainty (worse).
Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).
Memory for Treatment Content (youth-report)
Vignette-based, multiple-choice assessment of memory for exposure-CBT principles, scored as proportion correct (0-100%); higher scores indicate better memory for treatment content (better).
Time frame: End of active BraveBot period (average of ~6 weeks, max of 12 weeks) and follow-up (3 weeks later).
Developmentally Adapted or Original Version of the System Usability Scale (SUS) (youth- and clinician-report)
Standardized usability measure of the BraveBot system (developmentally adapted for youth; standard version for clinicians). Score range 0-100; higher scores indicate better perceived usability (better).
Time frame: End of active BraveBot period for youth (i.e., ~6 weeks on average, max of 12 weeks); end of study for clinicians (anticipated to be one year after recruitment begins).
Global Post-BraveBot Peference/Acceptability ratings (youth-report)
Youth-reported 0-100 slider ratings comparing BraveBot-assisted vs. self-guided exposure (e.g., effort, persistence, understanding, helpfulness, enjoyment, preference, future use, safety, willingness to recommend). Each item: minimum 0, maximum 100; higher scores indicate a more favorable rating of BraveBot.
Time frame: End of active BraveBot period (i.e., ~6 weeks on average, max of 12 weeks).
Clinician Attitudes Toward AI
Clinician-reported AI-attitudes scale at orientation (items rated on 1-5 scale; total scores range from 7 to 35); higher scores indicate more favorable attitudes.
Time frame: At baseline (orientation) and end of study (anticipated to be one year after recruitment begins)
Clinician Questionnaire - Global Feedback on BraveBot
0-100 global ratings of BraveBot's effects on exposure homework, workflow fit, acceptability, and clinical alignment, plus open-text feedback; higher scores indicate more favorable ratings.
Time frame: End of study (anticipated to be one year after recruitment begins).
Novel Parent/Caregiver Perceptions of BraveBot Questionnaire
For parents/caregivers of youth participants under 18 years of age, 0-100 sliders comparing BraveBot-supported vs self-guided exposure homework (e.g., child willingness/engagement, persistence during distress, independence from parent, parent-child conflict/stress, structure/guidance, comfort/appropriateness, future preference, and concerns about AI).
Time frame: At the end of the youth participant's active BraveBot period (i.e., ~6 weeks on average, max of 12 weeks).
Number of Automated Safety Alerts
Count of automated safety alerts generated by BraveBot's risk-detection workflow during BraveBot-assisted exposures. Reported as a count.
Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).
Clinician Response Time to Safety Alerts
Time from generation of an automated safety alert to documented clinician review, in hours. Reported as hours.
Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).
Proportion of Safety Alerts Classified as True Positive vs. False Positive
Among automated safety alerts reviewed by clinicians, the proportion classified as genuine concern (true positive) vs. false positive. Reported as a percentage.
Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).
Number of Clinician-Initiated Manual Safety Flags
Count of safety concerns flagged by clinicians that were not captured by the automated workflow (potential false negatives). Reported as a count.
Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).
Number of Youth-Reported "I Felt Unsafe" Responses
Count of post-exposure surveys on which a youth endorsed the "I felt unsafe" item. Reported as a count.
Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).
Plan to share: No — No routine sharing of individual participant data is planned at this time. De-identified, coded analytic datasets may be shared with named collaborators (Harvard University and TheraLoop AI, Inc.) under appropriate agreements and IRB approval. No deposit of individual-level data in public repositories is planned.
Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 5 months is below that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Feb 2027, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →